Pay in 4 interest-free payments of $5.63 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
By helping patients who suffer from obesity or at least one weight-related condition lose a significant amount of weight, these medications allow for a multitude of health benefits that have the potential to create long-term wellness improvements
Patients using these formulations should understand they are investigational and not equivalent to FDA-approved products
Review constipating drugs with your clinician and consider a short trial of a stool softener if symptoms emerge
FDA in May 2022 for type 2 diabetes
Tell your healthcare provider if your symptoms are very bothersome or are not getting better after a few weeks
A randomized, double-blind, placebo-controlled phase 2 study comparing the efficacy and safety of tirzepatide versus placebo in 196 patients with nonalcoholic steatohepatitis (SYNERGY-NASH) with or without diabetes is currently underway and is estimated to complete in 2024
US$ 22.00
US$ 22.66
US$ 25.17
US$ 22.54
US$ 21.30
US$ 24.34
US$ 25.93
US$ 28.21
